ICP
RXRX icon

Interchange Capital Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Interchange Capital Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$600 Buy
+600
New +$2.32K ﹤0.01% 301
2025
Q2 		– Sell
-600
Closed -$600 – 311
2025
Q1 		$600 Sell
600
-600
-50% -$4.37K ﹤0.01% 292
2024
Q4 		$8.11K Buy
1,200
+600
+100% +$4.03K ﹤0.01% 265
2024
Q3 		$3.95K Buy
+600
New +$4.3K ﹤0.01% 282

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Interchange Capital Partners's RXRX Position: Q1 2026 in Review

Interchange Capital Partners increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, buying an estimated $11.6K and bringing the position to 23,464 shares worth $124K. The position accounts for 0.04% of the portfolio, ranked #275.

Interchange Capital Partners first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $332K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Interchange Capital Partners held 23,464 shares of Recursion Pharmaceuticals worth $124K as of Q1 2026.
  • Interchange Capital Partners bought 3,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $11.6K.
  • Recursion Pharmaceuticals made up 0.04% of Interchange Capital Partners's portfolio in Q1 2026, its #275 holding.
  • Interchange Capital Partners first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Interchange Capital Partners's Recursion Pharmaceuticals position peaked at $332K in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Interchange Capital Partners's 13F filing for Q1 2026, filed 24 Apr 2026.